An 18F-MD-PSMA (Multi-dentate PMSA Imaging Agent) PET/CT in Prostate Cancer Relapse: Results of a Retrospective Trial.

HongLiang Fu,Sheng Liang,MiaoMiao Xu, Jun Guo,Qiang Liu,Jian Kang,LinLin Zhang,ZiHao Liu,Lin Ding,YuFei Ma,Bin Yang,Xudong Yao,Jun Qi,Hui Wang, YongQuan Cai

Current radiopharmaceuticals（2023）

引用 0|浏览15

暂无评分

摘要

An 18F-MD-PSMA as a radioligand was found to be superior to 11C-choline in the setting of patients with biochemical relapse after previous treatment. Its PET imaging results matched those of established PSMA radioligands, but its chemical structure was found to have added features to conjugate with other functional molecules, such as those with therapeutic properties. This radioligand lays the foundation for our further work.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要